Drug Policy Watch · State Brief 2026

New York

Snapshot (structured)

Adult-use cannabis: Legal since March 31, 2021 (Marihuana Regulation and Taxation Act, MRTA); retail sales began late 2022; 683 adult-use dispensaries open (OCM via the Cannabis Control Board, July 2, 2026) and more than $3.3 billion in total sales since launch.
Medical cannabis: Legal (program predates MRTA, expanded by it); reduced state excise tax of 3.15 percent for patients.
Home grow: Legal for adults 21+ (up to 3 mature and 3 immature plants per adult, 12 per household); adult-use home cultivation rules took effect June 2024.
Intoxicating hemp / hemp THC: Heavily restricted; New York prohibits intoxicating hemp-derived cannabinoids (delta-8, delta-10, HHC, THCP and similar) outside the licensed cannabis system.
Psychedelics: Not decriminalized statewide; no therapeutic-access program yet; multiple bills pending (A2142, S495 and related).
Broad decriminalization: Cannabis decriminalized and legalized; no broad decriminalization of other controlled substances.
Harm reduction: Strong (syringe services, broad naloxone access, fentanyl test strips legal; two overdose prevention centers operating in NYC in legal limbo, not state-authorized).
Governor (party): Kathy Hochul (Democrat).
Legislature control: Democratic trifecta; Senate roughly 41-22 Democratic, Assembly roughly 103-47 Democratic.
Citizen ballot initiatives allowed: No. New York does not allow citizen-initiated statutory or constitutional ballot measures.
Enclosure pressure score: 3/5

Cannabis

New York legalized adult-use cannabis when Governor Cuomo signed the Marihuana Regulation and Taxation Act (MRTA) on March 31, 2021, which created the Office of Cannabis Management (OCM) under the Cannabis Control Board to regulate adult-use, medical, and hemp cannabis [https://cannabis.ny.gov/cannabis-law-overview] [https://www.mpp.org/states/new-york/new-yorks-marijuana-regulation-and-taxation-act-(2021)/]. Adults 21+ may possess up to 3 ounces of flower or 24 grams of concentrate [https://www.mpp.org/states/new-york/].

Medical cannabis remains legal under a program that predates MRTA and was expanded by it (added qualifying conditions, whole-flower products). The medical excise tax was reduced from 7 percent to 3.15 percent effective June 1, 2024, and medical patients are exempt from the adult-use retail excise taxes [https://tax.ny.gov/bus/mc/medical-cannabis-tax.htm] [https://cannabispromotions.com/taxes/states/new-york].

Home grow: Adults 21+ may cultivate up to 3 mature and 3 immature plants each, capped at 6 mature and 6 immature per household. Adult-use home cultivation regulations took effect in June 2024; medical patient home grow rules were finalized earlier (2022) [https://norml.org/news/2022/09/22/new-york-state-regulators-finalize-home-cultivation-rules-for-qualified-patients/] [https://www.treehousecannabis.com/blog/home-grow-in-ny-2025-timelines-plant-counts-and-permit-basics].

Market structure: New York generally prohibits vertical integration. The exceptions are microbusinesses (Cannabis Law section 73) and the medical "registered organizations" (ROs), which hold a bespoke Registered Organization Dispensing (ROD) license permitting them to cultivate, process, distribute AND retail (Cannabis Law section 68-a), with up to three co-located adult-use stores (9 NYCRR 123.18) and up to eight medical dispensing sites (Cannabis Law section 35(8)); there is NO statutory cap on the number of ROs. Cannabis Law section 35 sets no limit, and section 35(9) directs the board to "register additional registered organizations" to serve unserved and underserved areas [https://www.nysenate.gov/legislation/laws/CAN/35]. As of OCM's 2025 Annual Report (December 2025), 19 ROs are approved; the Cannabis Control Board's May 29, 2026 renewal resolution lists 8 with live registrations [https://cannabis.ny.gov/system/files/documents/2025/12/ocm-annual-report_final-2025.pdf]. Taxes: a 9 percent state retail excise tax plus a 4 percent local retail excise tax, on top of which combined effective rates run roughly 13 to 21 percent depending on local cannabis taxes. New York replaced its earlier THC-potency tax with a 9 percent ad valorem wholesale excise tax (the potency tax repeal took effect for the 2024-2025 cycle) [https://cannabispromotions.com/taxes/states/new-york] [https://www.marijuanamoment.net/new-york-governor-proposes-repealing-marijuana-potency-tax-to-reduce-costs-and-combat-illicit-market/].

Key 2026 actions: The Cannabis Control Board extended all provisional CAURD and adult-use licenses through December 31, 2026, to give licensees more time to secure compliant locations [https://www.distru.com/cannabis-blog/new-york-state-of-cannabis-market-2025]. In late March 2026 the board announced a $6 million Equity Business Development Grant Program (awards up to about $30,000) targeting CAURD and supply-side Social and Economic Equity licensees [https://cannabis.ny.gov/system/files/documents/2026/03/march-ccb-press-release.pdf]. Hochul's 2026 State of the State announced a $17 million investment to expand Social and Economic Equity initiatives [https://www.governor.ny.gov/news/governor-hochul-marks-five-years-marihuana-regulation-and-taxation-act-new-york-advances]. Year-to-date adult-use sales exceeded $553 million through April 2026; 683 adult-use dispensaries were open as of the July 2, 2026 Cannabis Control Board meeting [https://www.cannabisequipmentnews.com/home/news/22962289/new-york-cannabis-sales-off-to-hot-start-in-2026].

Hemp

New York bans intoxicating hemp-derived cannabinoids (delta-8, delta-10, HHC, THCP, THCB and similar) outside the licensed adult-use cannabis system, regulating cannabinoid hemp through OCM's Cannabinoid Hemp Program, which licenses processing, manufacturing, and retail and sets manufacturing, testing, and labeling standards [https://cannabis.ny.gov/cannabinoid-hemp] [https://burningdaily.com/blogs/learn/new-york-cannabis-hemp-laws].

Exposure to federal hemp changes: The 2025 federal hemp amendments replace the prior delta-9-only test with a total-THC standard (measured after decarboxylation) and cap finished consumer products at 0.4 mg total THC per retail container, effective November 12, 2026 [https://scarincihollenbeck.com/client-alert/federal-hemp-ban-signed-into-law-enforcement-timeline-impacts-and-strategies]. Because New York is already restrictive on intoxicating hemp, analysts expect the state to need little adaptation when federal enforcement begins; OCM published a 2026 FAQ on the federal change [https://cannabis.ny.gov/system/files/documents/2026/01/hemp-2025-federal-law_faq-1-pager_260109.pdf].

Psychedelics

New York has not decriminalized psychedelics statewide and has no operating therapeutic-access program. Several bills are pending in the 2025-2026 session: - A2142 (Assemblymember Amy Paulin, with co-sponsors reported as Donna Lupardo and Andrew Hevesi) would allow growth, cultivation, and regulated adult use of psilocybin for treatment of certain health conditions, create a permit and licensure system, and remove psilocybin from the state controlled-substance schedule [https://www.nysenate.gov/legislation/bills/2025/A2142] [https://trackbill.com/bill/new-york-assembly-bill-2142-allows-the-growth-cultivation-and-adult-use-of-psilocybin-for-the-treatment-of-certain-health-conditions/2606559/]. - S495 / S00495 relates to medical use of psilocybin and establishes a psilocybin-assisted therapy grant program; reported sponsors include Senators Fernandez, Scarcella-Spanton, Comrie, Jackson, Myrie, and Salazar [https://www.nysenate.gov/legislation/bills/2025/S495] [https://legiscan.com/NY/text/S00495/2025]. - A separate "Psilocybin Assisted Therapy Pilot Program Act" concept would fund psilocybin-assisted therapy for veterans, first responders, and people with cluster headaches via the Department of Health and SUNY academic health centers, with a reported $5 million appropriation; advocates pushed an amended medical-psilocybin measure before the session ended June 4, 2026 (specific bill number unconfirmed for this exact pilot framing) [https://www.cityandstateny.com/policy/2026/05/room-shrooms-medical-psilocybin-access-eyed-after-budget-rush/413591/].

Broader drug policy

Broad decriminalization: Beyond cannabis, New York has not broadly decriminalized possession of other controlled substances.

Harm reduction: New York operates syringe service programs, broad naloxone access, and permits fentanyl test strips. Two overdose prevention centers (OnPoint NYC, in Washington Heights and East Harlem) have operated since November 2021 as the first publicly recognized such centers in the US, but they remain in legal and regulatory limbo because they were never state-authorized [https://onpointnyc.org/] [https://www.crainsnewyork.com/health-pulse/new-york-city-not-closing-door-safe-injection-sites-despite-opposition-hochul]. Governor Hochul has declined to direct state opioid-settlement funds to these centers, and there is renewed federal pressure to close them under the current administration; a member of New York's congressional delegation reportedly asked the US attorney general to shut them down [https://abc7ny.com/post/president-trump-asked-shut-down-overdose-prevention-centers-have-operated-3-years-nyc/15907033/].

Sentencing and expungement: The Cannabis Law automatically expunges and seals records for conduct no longer criminalized, with no action required by individuals. More than 200,000 convictions have been sealed, with roughly 107,000 additional records suppressed pending sealing [https://cannabis.ny.gov/cannabis-law-overview] [https://www.governor.ny.gov/news/governor-hochul-marks-five-years-marihuana-regulation-and-taxation-act-new-york-advances].

Overdose and treatment policy: Cannabis tax revenue funds drug treatment, public education, and community reinvestment; a Community Grant Reinvestment Fund directs reinvestment to disproportionately impacted communities (reported at roughly $10 million in total, with $5 million awarded and $5 million more available) [https://www.governor.ny.gov/news/governor-hochul-marks-five-years-marihuana-regulation-and-taxation-act-new-york-advances].

Political landscape

Governor: Kathy Hochul (Democrat) [https://en.wikipedia.org/wiki/202nd_New_York_State_Legislature]. Party control: Democratic trifecta, with the Senate roughly 41-22 Democratic and the Assembly roughly 103-47 Democratic [https://ballotpedia.org/2026_New_York_legislative_session]. Senate Majority Leader Andrea Stewart-Cousins (D) and Assembly Speaker Carl Heastie (D) lead the chambers [https://ballotpedia.org/2026_New_York_legislative_session].

Key committees: Cannabis-related measures typically move through the Senate and Assembly committees handling health, cannabis, and tax/finance matters; specific committee assignments for the bills above are unconfirmed here and should be verified on each bill's page.

Reform champions: Senator Jeremy Cooney is a leading cannabis voice and is pushing repeal of the medical cannabis excise tax (S3135/A4764) [https://mjbizdaily.com/news/push-to-repeal-new-york-medical-cannabis-tax-amid-crisis-claims/615087/]. On psychedelics, Assemblymember Amy Paulin (A2142) and the Senate sponsors of S495 are the named advocates [https://www.nysenate.gov/legislation/bills/2025/A2142]. Governor Hochul has positioned herself as supportive of an equity-driven cannabis market and proposed eliminating the potency tax to lower prices and fight the illicit market [https://www.marijuanamoment.net/new-york-governor-proposes-repealing-marijuana-potency-tax-to-reduce-costs-and-combat-illicit-market/].

Named opponents: Hochul has opposed using state opioid-settlement funds for overdose prevention centers, and a member of New York's congressional delegation (reported as Rep. Nicole Malliotakis) has urged federal closure of NYC's overdose prevention centers [https://abc7ny.com/post/president-trump-asked-shut-down-overdose-prevention-centers-have-operated-3-years-nyc/15907033/] [https://www.crainsnewyork.com/health-pulse/new-york-city-not-closing-door-safe-injection-sites-despite-opposition-hochul]. Broader named legislative opponents of cannabis or psychedelic reform are unconfirmed here.

Ballot initiatives

New York does not allow citizen-initiated statutory or constitutional ballot measures; constitutional amendments must originate in the legislature (passing two consecutive sessions) before going to voters. There are therefore no pending citizen-initiated cannabis, psychedelic, or drug-policy ballot measures for 2026. Reform in New York runs through the legislature and regulators, not the ballot box.

Equity and expungement

Social-equity licensing: MRTA set a goal of awarding 50 percent of adult-use licenses to social and economic equity applicants (people from communities disproportionately impacted by prohibition, minority- and women-owned businesses, distressed farmers, and service-disabled veterans). The CAURD program (348 licensees issued, no longer accepting applications) prioritized justice-involved individuals and those harmed by past enforcement [https://cannabis.ny.gov/licensing] [https://www.distru.com/cannabis-blog/new-york-state-of-cannabis-market-2025]. New York added equity supports in 2026: a $6 million Equity Business Development Grant Program and a proposed $17 million equity investment [https://cannabis.ny.gov/system/files/documents/2026/03/march-ccb-press-release.pdf] [https://www.governor.ny.gov/news/governor-hochul-marks-five-years-marihuana-regulation-and-taxation-act-new-york-advances].

Expungement: Automatic and petition-free. Records for conduct no longer criminalized are automatically expunged or sealed, with more than 200,000 convictions sealed and about 107,000 more suppressed pending sealing [https://cannabis.ny.gov/cannabis-law-overview]. Who benefits: people with prior low-level cannabis convictions and equity applicants; who is excluded or strained: many equity and CAURD licensees have struggled to find capital and compliant real estate, and reporting notes more than $6 million in social-equity tax funds sitting unspent [https://www.aol.com/6m-social-equity-tax-funds-233241595.html].

Market and barriers

Taxes: 9 percent state retail excise plus 4 percent local retail excise; combined effective rates roughly 13 to 21 percent with local cannabis taxes. Wholesale 9 percent ad valorem excise replaced the former THC-potency tax. Medical excise tax reduced to 3.15 percent (with active legislation to repeal it entirely) [https://cannabispromotions.com/taxes/states/new-york] [https://tax.ny.gov/bus/mc/medical-cannabis-tax.htm].
Registered organizations (the vertically integrated medical/MSO class): NO statutory cap. Cannabis Law section 35 sets no limit and section 35(9) mandates registering MORE of them [https://www.nysenate.gov/legislation/laws/CAN/35]. 19 approved; 8 with live registrations (CCB Resolution 2026-37, May 29, 2026). The historical figure of ten was a count reached under the repealed Compassionate Care Act, never a ceiling.
Vertical integration: barred for the ordinary supply chain (Cannabis Law section 80). Two carve-outs: microbusinesses (section 73) and the registered organizations, which hold a statutory vertical-integration license, the ROD (section 68-a). The law did not fence out the integrated operators; it wrote them their own lane.
Licensees / market size: 683 adult-use dispensaries open (CCB, July 2, 2026); roughly 28 medical dispensaries; 348 CAURD licenses issued; more than $3.3 billion in total program sales since launch; $553 million-plus YTD adult-use sales through April 2026 [https://www.cannabisequipmentnews.com/home/news/22962289/new-york-cannabis-sales-off-to-hot-start-in-2026] [https://www.distru.com/cannabis-blog/new-york-state-of-cannabis-market-2025].
License fees, capital, and residency requirements: specific dollar fee schedules and any residency or capital thresholds are not fully confirmed in the sources reviewed; consult OCM licensing for current fee tables [https://cannabis.ny.gov/licensing].

Enclosure read

New York sits in the middle of the enclosure spectrum, and it is a more complicated case than it first appears. Some of the design is genuinely open: home grow is legal for ordinary adults, expungement is automatic and petition free, and a large CAURD and equity cohort was deliberately put first in line. But the statute did NOT contain the integrated operators. It wrote them a bespoke vertical-integration license (the ROD, Cannabis Law section 68-a), raised their dispensing sites from four to eight, let them into adult-use retail, and set NO cap on their number while directing the board to register more of them (section 35(9)). The often-repeated claim that New York capped its multistate operators is false, and we repeated it ourselves until July 14, 2026.

The fencing pressure comes from execution and economics, not statute. Equity and CAURD licensees have been squeezed by capital scarcity, real-estate and proximity rules, repeated provisional-license extensions (now through December 2026), high effective tax rates that feed the illicit market, and equity funds sitting unspent. The result is that the people the law meant to seat at the table are the ones most at risk of being washed out, while the ROs sit in an odd position of their own: privileged by an uncapped legal lane and the only slice of federal tax relief, yet tied to a medical program that is itself shrinking (sales down 41 percent since 2023, patients down 21 percent in a year, two of the original ten operators gone). That is an asymmetry of incentive, not a conquest. Intoxicating hemp is firmly fenced into the licensed system, removing a low-barrier path for small sellers. Net: the legal architecture is open in parts and quietly permissive toward the integrated incumbents, and the lived market is moderately fenced. Score: 3/5.

What to watch next

December 31, 2026: provisional CAURD and adult-use license extension deadline; watch for further extensions or enforcement [https://www.distru.com/cannabis-blog/new-york-state-of-cannabis-market-2025].
November 12, 2026: federal total-THC hemp standard and 0.4 mg per container cap take effect; watch New York alignment and enforcement posture [https://scarincihollenbeck.com/client-alert/federal-hemp-ban-signed-into-law-enforcement-timeline-impacts-and-strategies].
Psychedelic bills (A2142, S495, pilot proposals): the 2026 session reportedly ran through about June 4, 2026; carryover into the 2025-2026 biennium means these can advance again before the session formally ends; status should be rechecked on the bill pages [https://www.cityandstateny.com/policy/2026/05/room-shrooms-medical-psilocybin-access-eyed-after-budget-rush/413591/].
Medical cannabis tax repeal (S3135/A4764): watch whether it advances or is folded into a future budget; the 3.15 percent tax remained in place as of mid-2026 [https://mjbizdaily.com/news/push-to-repeal-new-york-medical-cannabis-tax-amid-crisis-claims/615087/].
Overdose prevention centers: watch for federal enforcement action and any state authorization or defunding decisions [https://abc7ny.com/post/president-trump-asked-shut-down-overdose-prevention-centers-have-operated-3-years-nyc/15907033/].
The New York Legislature convenes annually in January; the next regular session begins January 2027.

Regulators

Office of Cannabis Management (OCM) and the Cannabis Control Board: regulate adult-use, medical, and cannabinoid hemp programs [https://cannabis.ny.gov/].
OCM Cannabinoid Hemp Program: licenses hemp processing, manufacturing, and retail [https://cannabis.ny.gov/cannabinoid-hemp].
New York State Department of Taxation and Finance: administers cannabis excise taxes [https://tax.ny.gov/bus/mc/medical-cannabis-tax.htm].
New York State Department of Health: psychedelic therapy proposals and harm-reduction / overdose programs would run through DOH; drug treatment and overdose policy also involve the Office of Addiction Services and Supports (OASAS).

Federal exposure (2026)

New York is a fully legal adult-use and medical state operating under federal cannabis prohibition, so the gap between Albany law and Washington law defines its exposure.

Rescheduling and 280E. The DOJ/DEA order signed April 22, 2026 and effective April 28, 2026 (91 FR 22714) moved only FDA-approved cannabis drugs and state-licensed medical cannabis to Schedule III; recreational cannabis stays Schedule I. By design this is medicalize-and-control, not legalization: it does not allow interstate commerce, does not touch the adult-use businesses that make up the bulk of New York's roughly $3.3 billion market, and ends Section 280E (the rule denying ordinary business deductions to sellers of Schedule I/II drugs) only for the medical category. In New York that 280E relief lands on the registered organizations (ROs), the only holders of state medical licenses: 19 approved, 8 with live registrations, and realistically about four dual-license operators actually serving adult-use customers today. It is a small, well-capitalized club, and it is not capped. Adult-use retailers, microbusinesses, CAURD licensees, and Social and Economic Equity (SEE) licensees keep paying federal tax with no deductions, so the relief flows to the largest, best-capitalized incumbents and skips the equity cohort the state put first in line. The broader DEA rescheduling hearing opened June 29, 2026 and may slip to 2027; even if it broadens, Schedule III still would not legalize recreational sale or open interstate commerce [https://cannabis.ny.gov/cannabis-law-overview].

The November 12, 2026 hemp cliff. FY2026 federal agriculture appropriations (Sec. 781, reported sponsor Rep. Andy Harris R-MD, unconfirmed exact attribution) narrow hemp to a total-THC standard of about 0.4 mg THC per container, recriminalizing roughly 90 to 95 percent of intoxicating hemp products effective November 12, 2026; the H.R.7010 delay was not enacted and the 2026 Farm Bill (H.R.7567, unconfirmed) keeps the ban [https://scarincihollenbeck.com/client-alert/federal-hemp-ban-signed-into-law-enforcement-timeline-impacts-and-strategies]. New York is already one of the most restrictive states here: it fences intoxicating hemp-derived cannabinoids (delta-8, delta-10, HHC, THCP and similar) into the licensed cannabis system through OCM's Cannabinoid Hemp Program [https://cannabis.ny.gov/cannabinoid-hemp]. Practical effect: the federal cliff mostly closes a gray-market channel New York had already shut, so the state needs little statutory adaptation, but the federal floor hardens the enclosure by removing any low-barrier hemp path nationwide. OCM published a 2026 FAQ on the federal change [https://cannabis.ny.gov/system/files/documents/2026/01/hemp-2025-federal-law_faq-1-pager_260109.pdf].

Banking. SAFER Banking remains stalled in Congress, so state-legal cannabis businesses in New York still face restricted access to banks, card networks, and ordinary commercial credit, and remain cash-intensive. The capital squeeze falls hardest on exactly the operators New York prioritized: CAURD and SEE licensees, who already struggle to raise money and secure compliant real estate, with more than $6 million in social-equity tax funds reported sitting unspent [https://www.aol.com/6m-social-equity-tax-funds-233241595.html]. No federal banking fix and no federal tax relief for adult-use leaves equity licensees structurally undercapitalized against the ROs.

Psychedelics. New York's psilocybin bills (A2142 in the Assembly, S495 in the Senate) would create state access through cultivation, licensure, and a therapy grant program, but neither is enacted and both depend on the state legislature, not the ballot [https://www.nysenate.gov/legislation/bills/2025/A2142] [https://www.nysenate.gov/legislation/bills/2025/S495]. The federal pathway is separate and narrower: psilocybin, MDMA, and ibogaine remain Schedule I, and while the April 18, 2026 executive order, Accelerating Medical Treatments for Serious Mental Illness [https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/] plus FDA priority vouchers fast-track FDA review, there is no approval yet. So any near-term New York access would have to come from the state bills clearing prohibition at the state level, not from a federal approval.

Harm reduction. New York's harm-reduction posture is strong: syringe service programs, broad naloxone access, and legal fentanyl test strips, plus the two OnPoint NYC overdose prevention centers operating since 2021 [https://onpointnyc.org/]. Those centers sit in federal legal limbo because they were never state-authorized and remain exposed to federal enforcement, with a member of New York's congressional delegation (reported as Rep. Nicole Malliotakis) urging the U.S. attorney general to close them [https://abc7ny.com/post/president-trump-asked-shut-down-overdose-prevention-centers-have-operated-3-years-nyc/15907033/]. New York is also directly exposed to the SAMHSA "Dear Colleague" guidance of April 24, 2026, which bars federal grant funds for fentanyl test strips, sterile syringes, and sterile water (naloxone still supported); state and local programs reliant on SAMHSA dollars must now backfill with state, settlement, or local money to sustain those services [https://www.statnews.com/2026/04/27/trump-administration-samhsa-clear-shift-from-harm-reduction/] [https://www.naco.org/news/samhsa-implements-new-harm-reduction-restrictions-updated-guidance].

Patient access and rights

This section covers what New York law does and does not protect for a medical cannabis patient: use inside a hospital, and the broader rights that follow a patient into work, housing, parenting, an organ transplant list, and school. It is information, not legal advice, and it reflects the law as of July 2026. Each point links to the primary statute.

Hospital access (Ryan's Law): New York has no Ryan's Law statute, but it does have a regulatory allowance that the seven Ryan's Law states do not frame the same way. Under the Department of Health's hospital regulations (10 NYCRR Part 405) and guidance (DAL 18-01), a hospital may permit a certified medical cannabis patient to self-administer their own certified product while admitted. This is a discretion, not a right: the hospital may allow it, but no law requires the hospital to, and a facility may still say no. Seven states have enacted a binding Ryan's Law protection (California in 2021, and Colorado, Delaware, Louisiana, Oregon, Virginia, and Washington in 2026); New York's allowance is weaker than those because it leaves the decision with the hospital.

Broader protections: New York's protections are narrower than several of its neighbors'. They sit in Cannabis Law Section 42, where the Marihuana Regulation and Taxation Act consolidated them. Employment is protected (Section 42(2)), which bars an employer from penalizing a certified patient based solely on their lawful, authorized use, and parental and custody rights are protected (Section 42(3)). Section 42(1) states a general rule that certified patients are not subject to penalty solely for their authorized use, but the statute does not add specific guarantees for the remaining areas. A review of Cannabis Law Section 42 found no dedicated protection for housing, placement on an organ transplant list, or school enrollment. Those gaps are the finding.

Out-of-state patients: New York does not offer medical reciprocity. Adults 21 and over may purchase at licensed adult-use retailers, but an out-of-state patient does not receive the medical patient protections described above.

The federal picture: the April 2026 federal move of state-licensed medical cannabis to Schedule III did not change any of this. Schedule III does not make dispensary cannabis a lawful prescription medicine and does not create any hospital-use right; only state law can force hospital access, and New York has a discretionary regulatory allowance rather than a binding Ryan's Law statute. The broader protections above are a creature of New York law, not federal law.

Sources: New York patient protections, N.Y. Cannabis Law Section 42; hospital self-administration allowance, 10 NYCRR Part 405 and New York State Department of Health guidance DAL 18-01.

Analysis: the enclosure read in depth

Who is fenced out and who consolidates. New York's market design is often described as anti-consolidation, and in part it is: home grow is legal for ordinary adults, expungement is automatic, and a large CAURD and SEE cohort was placed first in line. But the statute also wrote the incumbent medical operators a bespoke vertical-integration license (the ROD, Cannabis Law section 68-a), raised their dispensing sites from four to eight (section 35(8)), let them into adult-use retail, and directed the board to register MORE of them (section 35(9)). It did not fence out the integrated class. It built it a lane. The equity-first licensing and the vertical-integration ban on the ordinary supply chain do reserve real ground for small operators, and that part is genuine. But the consolidation pressure runs the other way, and the federal levers sharpen it. The April 2026 Schedule III move hands 280E relief to the medical ROs only, the most concentrated and best-capitalized players, while adult-use and equity licensees keep eating non-deductible federal tax. Stalled SAFER Banking keeps equity operators starved of capital and credit. High effective retail taxes (roughly 13 to 21 percent combined) feed an illicit market that undercuts licensed equity stores. The people the law meant to seat at the table, CAURD and SEE licensees, are the ones most at risk of being washed out. The ROs hold both the integration carve-out and the only slice of federal tax relief, though their own program is contracting. The fence here is a standing incentive, not yet a completed capture.

State-plus-federal interaction. The state architecture is open in parts, but it carved out its incumbent medical operators from the vertical-integration ban, and it sits inside a federal frame that favors large incumbents and fences out small actors and hemp. Federal medicalize-and-control rewards the ROs; federal banking inaction starves the equity cohort; the federal hemp cliff removes a low-barrier path nationwide and reinforces the licensed-system enclosure New York already built; and federal harm-reduction cuts (SAMHSA) plus enforcement pressure on the OnPoint NYC centers push against the state's most open, commons-style public-health programs. The net is that New York's open design is partly neutralized by the federal environment, and the benefits of federal change accrue to the few integrated incumbents, a class the state never capped.

What to watch. The December 31, 2026 provisional CAURD and adult-use license deadline is the single most important state inflection: if those provisional licensees cannot convert to compliant locations and funding by then, the equity cohort could thin out sharply right as the ROs gain 280E relief, accelerating quiet consolidation. Also watch the June 29, 2026 DEA hearing (and any 2027 slip), the November 12, 2026 hemp cliff and New York's enforcement posture, whether the psilocybin bills advance, the medical-tax repeal effort (S3135/A4764), and any federal action against the overdose prevention centers.

Commons counter-moves. New York retains real anti-enclosure features that justify a middle score rather than a high one: legal home grow for adults 21+ (3 mature and 3 immature plants per adult, 12 per household) gives ordinary people a non-market path that no federal lever touches; automatic, petition-free expungement has sealed more than 200,000 convictions with about 107,000 more pending, returning value to harmed communities without gatekeepers; and the partial anti-consolidation design (a vertical-integration ban for the ordinary supply chain, equity-first licensing, equity grants) is a real, if incomplete, defense against MSO capture. It is incomplete precisely because the registered organizations sit outside that ban, with their own vertical-integration license and no cap on their number. These are the live commons counter-moves.

Justifying the score. Home grow and automatic, petition-free expungement are real commons paths and they pull the score down. But the claim that the legal architecture is broadly anti-enclosure does not survive the statute: Cannabis Law wrote the incumbent medical class a vertical-integration license, expanded it, and mandated registering more of it. The lived market is also moderately fenced by capital scarcity, taxes, and the illicit market, and the 2026 federal levers (280E relief only for the ROs, stalled banking, the hemp cliff, SAMHSA harm-reduction cuts, and enforcement pressure on the OnPoint centers) all tilt toward the largest incumbents and against the equity cohort the state prioritized. That balance, open by design, moderately fenced in practice, and pressured by a consolidation-favoring federal frame, lands New York at 3/5.

Active legislation (2026)

This list is not exhaustive. For the full long tail, see the New York Senate bill search (https://www.nysenate.gov/legislation), LegiScan New York (https://legiscan.com/NY).

Beyond the live tracker

These measures are not in the live bill list below: some are not bills (executive orders, rules, referendums, or budgets), and some are proposals or prior-session measures the live tracker does not currently carry.

Medical marijuana program expansion (signed) Expands medical cannabis program with new rules on home grow, possession limits and more (Signed into law (2025-2026))

Bill	Title/Topic	Chamber	Status	Sponsor(s)
A2142 / A2142A	Allows growth, cultivation, and regulated adult use of psilocybin for certain health conditions; removes psilocybin from controlled-substance schedule	Assembly	Active in 2025-2026 session (in committee); not enacted	Amy Paulin (co-sponsors reported: Donna Lupardo, Andrew Hevesi) [https://www.nysenate.gov/legislation/bills/2025/A2142]
S495 / S00495	Medical use of psilocybin; psilocybin-assisted therapy grant program and appropriation	Senate	Active in 2025-2026 session (in committee); not enacted	Reported: Fernandez, Scarcella-Spanton, Comrie, Jackson, Myrie, Salazar [https://www.nysenate.gov/legislation/bills/2025/S495]
S7387	Authorizes retail dispensary, microbusiness, and nursery licensees to sell immature cannabis plants (up to 3 per person) to consumers for personal cultivation	Senate	Active in 2025-2026 session	Sponsor unconfirmed; see bill page [https://www.nysenate.gov/legislation/bills/2025/S7387]
S3135 / A4764	Repeals the medical cannabis excise tax (Tax Law sec. 490) and dissolves the medical cannabis trust fund	Senate / Assembly	Active; advocacy-stage, not enacted as of mid-2026	Senate sponsor reported: Jeremy Cooney; Assembly companion sponsor unconfirmed [https://mjbizdaily.com/news/push-to-repeal-new-york-medical-cannabis-tax-amid-crisis-claims/615087/]
A977 / A00977	Cannabis-related amendment (medical program / related); exact scope unconfirmed	Assembly	Active in 2025-2026 session	Sponsor unconfirmed; see Assembly bill page [https://nyassembly.gov/leg/?bn=A00977&term=2025]
A7998	Cannabis law amendment; exact scope unconfirmed	Assembly	Active in 2025-2026 session	Sponsor unconfirmed; see bill page [https://www.nysenate.gov/legislation/bills/2025/A7998]
Medical marijuana program expansion (signed)	Expands medical cannabis program with new rules on home grow, possession limits and more	Both (enacted)	Signed into law (2025-2026)	Sponsor(s) unconfirmed; signed by Gov. Hochul [https://www.marijuanamoment.net/new-york-governor-signs-bill-expanding-state-medical-marijuana-program-with-new-rules-on-home-grow-possession-limits-and-more/]

Support this work

This work is free and reader-funded. No paywalls, no ads. This brief is independent and fully sourced, and reader contributions are what keep the 50-state coverage current and answerable to readers, not advertisers or owners.

If it helped you, please chip in $5 to keep it going. Recurring support helps most; about $25 funds a full refresh of a state brief like this one.

Contribute $5 on Ko-fi Become a member

← Back to all 50 states and federal briefs

A planning snapshot for 2026, not legal advice. Policy moves quickly; confirm any single detail against the cited sources before acting on it. Sponsor names are given where confirmable and marked unconfirmed otherwise.

About the author. Jessica Mantonya is the founder of Drug Policy Watch and Hold in Common. She also advises operators, advocates, and funders on regulatory strategy and anti-enclosure positioning. Work with her →

Correction, July 14, 2026. An earlier version of this brief said New York's medical registered organizations (ROs) are "capped at 10 statewide, a deliberate limit on large multistate operator dominance." That was wrong, and it was backwards. There is no statutory cap on ROs. Cannabis Law section 35 sets no limit, and section 35(9) directs the board to "register additional registered organizations." The figure of ten was a historical count under the repealed Compassionate Care Act, never a ceiling. As of OCM's 2025 Annual Report, 19 ROs are approved; 8 hold live registrations. MRTA also expanded the ROs: it raised their dispensing sites from four to eight and let them into adult-use retail. Our source was a law firm blog that never mentions a cap; the statute says the opposite. We have corrected the market-structure, 280E, and enclosure-analysis passages, and updated the stale dispensary count (599 to 683). Cannabis Law section 35. The error was ours.